Rate My Professor Awen Gallimore

Gallimore's laboratory focuses on identifying correlates of anti-viral and anti-cancer immunity to inform novel treatments, addressing immunotherapy barriers like regulatory T cell suppression and poor tumor vascular access for immune cells. Her research progresses from animal models to patient testing, including COVID-19 studies on SARS-CoV-2 T cell responses. She holds the position of Cancer Theme Lead for the College of Life Sciences and teaches immunology through lectures, tutorials, and lab projects for medical and pharmacy undergraduates. Gallimore has contributed to international summer schools, such as the European Society of Immunology events and the John Humphreys Summer School in Cuba, and served as External Examiner for BSc Immunology at the University of Glasgow (2014-2018). Key publications include 'Optimising anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple negative breast cancer' (Lauder et al., 2026, Journal for ImmunoTherapy of Cancer); 'Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients' (Oliver et al., 2025, Cancer Immunology, Immunotherapy); 'Immuno-oncology' (Gallimore and Tournier, 2023, Essays in Biochemistry); and 'Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity' (Scurr et al., 2022, Nature Communications).